hologic , inc . notes to consolidated financial statements ( continued ) ( in thousands , except per share data ) the company has considered the provision of eitf issue no . 95-8 , accounting for contingent consideration paid to the shareholders of and acquired enterprise in a purchase business combination , and concluded that this contingent consideration represents additional purchase price . during the fourth quarter of fiscal 2007 the company paid approximately $ 19000 to former suros shareholders for the first annual earn-out period resulting in an increase to goodwill for the same amount . goodwill will be increased by the amount of the additional consideration , if any , when it becomes due and payable for the second annual earn-out . in addition to the earn-out discussed above , the company increased goodwill related to the suros acquisition in the amount of $ 210 during the year ended september 29 , 2007 . the increase was primarily related to recording a liability of approximately $ 550 in accordance with eitf 95-3 related to the termination of certain employees who have ceased all services for the company . approximately $ 400 of this liability was paid during the year ended september 29 , 2007 and the balance is expected to be paid by the end of the second quarter of fiscal 2008 . this increase was partially offset by a decrease to goodwill as a result of a change in the valuation of certain assets and liabilities acquired based on information received during the year ended september 29 , 2007 . there have been no other material changes to purchase price allocations as disclosed in the company 2019s form 10-k for the year ended september 30 , 2006 . as part of the purchase price allocation , all intangible assets that were a part of the acquisition were identified and valued . it was determined that only customer relationship , trade name , developed technology and know how and in-process research and development had separately identifiable values . customer relationship represents suros large installed base that are expected to purchase disposable products on a regular basis . trade name represent the suros product names that the company intends to continue to use . developed technology and know how represents currently marketable purchased products that the company continues to resell as well as utilize to enhance and incorporate into the company 2019s existing products . the estimated $ 4900 of purchase price allocated to in-process research and development projects primarily related to suros 2019 disposable products . the projects were at various stages of completion and include next generation handpiece and site marker technologies . the company has continued to work on these projects and expects they will be completed during fiscal 2008 . the deferred income tax liability relates to the tax effect of acquired identifiable intangible assets , and fair value adjustments to acquired inventory as such amounts are not deductible for tax purposes , partially offset by acquired net operating loss carry forwards that the company believes are realizable . for all of the acquisitions discussed above , goodwill represents the excess of the purchase price over the net identifiable tangible and intangible assets acquired . the company determined that the acquisition of each aeg , biolucent , r2 and suros resulted in the recognition of goodwill primarily because of synergies unique to the company and the strength of its acquired workforce . supplemental unaudited pro-forma information the following unaudited pro forma information presents the consolidated results of operations of the company , r2 and suros as if the acquisitions had occurred at the beginning of fiscal 2006 , with pro forma adjustments to give effect to amortization of intangible assets , an increase in interest expense on acquisition financing and certain other adjustments together with related tax effects: .

Table: 2006 net revenue $ 524340 net income 28649 net income per share 2014basic $ 0.55 net income per share 2014assuming dilution $ 0.33

.

Question: based on the eps , how many shares are estimated to be oustanding?
Answer: 52089.1
Calculation: divide(28649, 0.55)